中华肝脏病杂志
中華肝髒病雜誌
중화간장병잡지
CHINESE JOURNAL OF HEPATOLOGY
2013年
11期
821-824
,共4页
席宏丽%李敏然%鲍毅%于敏%秦小琪%徐小元
席宏麗%李敏然%鮑毅%于敏%秦小琪%徐小元
석굉려%리민연%포의%우민%진소기%서소원
肝炎,乙型,慢性%肝炎表面抗原,乙型%DNA,肝炎病毒,乙型%核苷(酸)类抗病毒药
肝炎,乙型,慢性%肝炎錶麵抗原,乙型%DNA,肝炎病毒,乙型%覈苷(痠)類抗病毒藥
간염,을형,만성%간염표면항원,을형%DNA,간염병독,을형%핵감(산)류항병독약
Hepatitis B,chronic%Hepatitis B surface antigen%HBV DNA%Nucleotide (acid) antivirus drug
目的 分析慢性乙型肝炎患者应用核苷(酸)类抗病毒药物治疗,动态观察HBVDNA与HBsAg定量.方法 110例慢性乙型肝炎患者初始应用单种核苷类药物抗病毒治疗,每三个月随访一次,检测HBV五项标志物、HBV DNA,每隔1年检测HBsAg定量,用SPSS13.0统计软件分析比较HBV DNA与HBsAg定量的5年变化.根据资料不同分别采用方差分析和x2检验进行统计学分析.结果 110例患者中,在随访第5年仍有90例应用单药治疗.HBeAg阳性的HBVDNA与HBsAg定量均高于HBeAg阴性的患者.随着抗病毒治疗时间的延长,慢性乙型肝炎患者的HBsAg和HBV DNA均有下降趋势(F值分别为17.1和151.53,P值均＜0.05),HBV DNA在随访第1年下降最明显.结论 HBeAg阴性和HBeAg阳性慢性乙型肝炎患者HBV DNA与HBsAg定量均随着核苷(酸)类抗病毒药物治疗时间的延长而下降;HBV DNA在治疗一年内下降幅度最大,HBsAg定量在随访后3年与基线水平比较,差异有统计学意义.
目的 分析慢性乙型肝炎患者應用覈苷(痠)類抗病毒藥物治療,動態觀察HBVDNA與HBsAg定量.方法 110例慢性乙型肝炎患者初始應用單種覈苷類藥物抗病毒治療,每三箇月隨訪一次,檢測HBV五項標誌物、HBV DNA,每隔1年檢測HBsAg定量,用SPSS13.0統計軟件分析比較HBV DNA與HBsAg定量的5年變化.根據資料不同分彆採用方差分析和x2檢驗進行統計學分析.結果 110例患者中,在隨訪第5年仍有90例應用單藥治療.HBeAg暘性的HBVDNA與HBsAg定量均高于HBeAg陰性的患者.隨著抗病毒治療時間的延長,慢性乙型肝炎患者的HBsAg和HBV DNA均有下降趨勢(F值分彆為17.1和151.53,P值均＜0.05),HBV DNA在隨訪第1年下降最明顯.結論 HBeAg陰性和HBeAg暘性慢性乙型肝炎患者HBV DNA與HBsAg定量均隨著覈苷(痠)類抗病毒藥物治療時間的延長而下降;HBV DNA在治療一年內下降幅度最大,HBsAg定量在隨訪後3年與基線水平比較,差異有統計學意義.
목적 분석만성을형간염환자응용핵감(산)류항병독약물치료,동태관찰HBVDNA여HBsAg정량.방법 110례만성을형간염환자초시응용단충핵감류약물항병독치료,매삼개월수방일차,검측HBV오항표지물、HBV DNA,매격1년검측HBsAg정량,용SPSS13.0통계연건분석비교HBV DNA여HBsAg정량적5년변화.근거자료불동분별채용방차분석화x2검험진행통계학분석.결과 110례환자중,재수방제5년잉유90례응용단약치료.HBeAg양성적HBVDNA여HBsAg정량균고우HBeAg음성적환자.수착항병독치료시간적연장,만성을형간염환자적HBsAg화HBV DNA균유하강추세(F치분별위17.1화151.53,P치균＜0.05),HBV DNA재수방제1년하강최명현.결론 HBeAg음성화HBeAg양성만성을형간염환자HBV DNA여HBsAg정량균수착핵감(산)류항병독약물치료시간적연장이하강;HBV DNA재치료일년내하강폭도최대,HBsAg정량재수방후3년여기선수평비교,차이유통계학의의.
Objective To analyze the dynamic changes in hepatitis B virus (HBV) DNA and hepatitis B surface antigen (HBsAg) levels in chronic hepatitis B (CHB) patients following treatment by antiviral nucleotide drugs over a 5-year follow-up period and to assess the clinical significance of quarterly and annual quantitative measurements.Methods One-hundred-and-ten patients with CHB were enrolled in the study and administered on-going standard mono-therapy with various antiviral nucleotide drugs.Over a 5-year period,the HBV DNA level was measured by quantitative PCR every three months and the HBsAg levels were measured by chemiluminescence once a year.The dynamic changes in HBV DNA and HBsAg levels were assessed by Chi-squared test and ANOVA.Results Only 90 of the CHB patients completed the 5-year follow-up and were included in the analysis.The patients who showed HBeAgpositivity at baseline (study start) had higher levels ofHBV DNA and HBsAg than the patients showing HBeAgnegativity.In general,the antiviral nucleotide drug therapy induced downward trends in HBsAg and HBV DNA level over time (F =17.1,151.53,all P ＜ 0.05).However,the most robust reduction in HBV DNA occurred during the fust year.The HBsAg level followed an opposite trend,with the most robust reductions occurring in the 3rd,4th and 5th years of treatment.Conclusion Long-term antiviral nucleotide mono-therapies induced decreases in HBV DNA and HBsAg levels in CHB patients,with the former being most reduced in the short-term and the latter in the long-term.
